Clinical study results

In an independent clinical study at Essex Testing Clinic, Inc. (2017), 31 women used Blue Copper 5 PRIME Face Cream twice daily for six weeks. Skin was assessed with calibrated instruments at baseline, immediately after the first application, and again at weeks 4 and 6. Every instrument change reported below was statistically significant versus baseline (p<0.05).

Photography of an individual user following twice-daily use. Individual results vary.

Instrument-measured, week 6 vs baseline. Essex Testing Clinic, 31 subjects, twice daily.

Measured results over 6 weeks

Measure	After 1st use	Week 4	Week 6	Improved
Crow’s-feet fine lines & wrinkles (Visia imaging)	−9.6%	−16.6%	−18.9%	100%
Skin moisture (Corneometer)	+78.9%	+73.4%	+94.2%	100%
Skin elasticity (Cutometer R2)	+22.3%	+14.5%	+28.0%	90%

All improvements were statistically significant versus baseline (p<0.05). “Improved” is the share of subjects showing improvement at week 6. No product-related irritation was observed on any subject at any visit.

What subjects reported at 6 weeks

After using the product…	Agreed
The appearance of fine lines and wrinkles is reduced	97%
My skin looks more moisturized	100%
My skin feels more hydrated	97%
My skin feels firmer	97%
Overall, my skin appears firmer	94%
Overall, my skin appears more radiant	97%
The texture of my skin feels smoother	98%
I would like to purchase this product	94%

Subject questionnaire, final (week 6) visit. Individual results vary.

Study design

Laboratory	Essex Testing Clinic, Inc. — independent testing facility (2017)
Subjects	31 women; all 31 completed the study
Duration	6 weeks, twice daily (AM & PM)
Measures	Visia CR imaging (crow’s-feet), Corneometer (moisture), Cutometer R2 (elasticity), technician irritation grading, subject questionnaire
Standard	Good Clinical Practice / 21 CFR Part 50; informed consent obtained

The ingredient evidence

Most anti-aging creams contain the right ingredients at the wrong strength. An active only does what its study says it does if it is present at the concentration that study used. Below is what is in PRIME Face, and what the research behind each active actually showed.

Matrikine peptide complex

Clinically dosed — above the level used in the research

A pairing of two matrikine peptides, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, which signal the skin to rebuild its extracellular matrix.

Subjects	2 panels of 23 volunteers, aged 39–74
Design	Half-face, placebo-controlled — the active on one side, placebo on the other
Regimen	Twice daily, 2 months
Method	Silicone-imprint skin topography

Supporting in-vitro work on the same active: collagen I +258%, fibronectin +164%, hyaluronic acid +179%. A separate 4-month study (2 × 30 volunteers) recorded wrinkle depth −27% at 4 months.

Firming peptide (acetyl tetrapeptide-2)

Clinically dosed — an exact match to the studied level

It works against gravity: increasing collagen and functional elastin synthesis, and overexpressing the genes behind the focal adhesions that hold skin cells together.

Subjects	Women aged 40–60 with sagging skin and loss of elasticity
Regimen	Twice daily, 56 days
Also recorded	Visible lifting of the face contour — a decrease of 0.13 cm

Artichoke-leaf peptides for hormonal ageing (Menofit®)

Studied for menopausal skin

Purified peptides from artichoke leaves, developed specifically for skin undergoing hormonal ageing. They help normalise keratinocyte growth and support the dermal matrix — maintaining skin thickness, hydration and smoothness as oestrogen declines.

Supplier studies of a 3% artichoke-leaf emulsion (in vivo) and menopausal-skin cell cultures (in vitro). These figures are for the ingredient, not the finished Osmotics product.

The copper peptide

PRIME Face contains copper tripeptide — the Blue Copper peptide Osmotics has built its science on since 1998. Copper peptides are among the few actives in cosmetic science with decades of independent, peer-reviewed literature behind them, beginning with Maquart’s demonstration of collagen synthesis in fibroblast cultures (FEBS Letters, 1988).

It also carries sh-oligopeptide-1 (EGF) and Copper PCA.

What we do not claim

One of the hydration actives on the label sits below the level its own research used. We therefore make no hydration claim for it, even though the ingredient is in the formula. An ingredient earns a claim by being clinically dosed — not by appearing on the box.

Sources: Sederma, Lipotec and SILAB supplier clinical studies; Essex Testing Clinic (finished-product consumer & instrument study, 2017).